GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Bentham Science Publishers Ltd.  (3)
  • 1
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2020
    In:  Letters in Drug Design & Discovery Vol. 17, No. 9 ( 2020-09-11), p. 1186-1196
    In: Letters in Drug Design & Discovery, Bentham Science Publishers Ltd., Vol. 17, No. 9 ( 2020-09-11), p. 1186-1196
    Abstract: The availability of antiviral medicines for the treatment of viral diseases is limited, hence the discovery of novel bioactive molecules is required. The present investigation has been carried out to develop novel 3-O-sulfotransferase enzyme inhibitors to treat viral diseases. Method: Virtual screening study (QSAR, docking and pharmacophore analysis) and binding mode analysis have been performed on a dataset collected from the literature (synthetic and natural compounds). Results: The docking studies showed that Glu184, His186, Lys215 and Lys368 residues established the most important hydrogen bonding with several hit compounds. The QSAR results explained that the presence of electronegative atoms/groups in the aromatic or heteroaromatic rings confer increased activity. Furthermore, the flexibility and the aromatic rings with less polar groups have better activity than the compounds connected to purine rings. Finally, the structurebased pharmacophore studies illustrated that the ligand has many polar interaction sites, and the projected acceptor and donor groups in the molecules make a significant contribution to the pharmacophore model building. Conclusion: These studies identified two compounds, Phomoidride B and Barceloneic acid A, as potential 3-OST inhibitors.
    Type of Medium: Online Resource
    ISSN: 1570-1808
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2020
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2006
    In:  Current Bioactive Compounds Vol. 2, No. 3 ( 2006-09-01), p. 243-261
    In: Current Bioactive Compounds, Bentham Science Publishers Ltd., Vol. 2, No. 3 ( 2006-09-01), p. 243-261
    Type of Medium: Online Resource
    ISSN: 1573-4072
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2006
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    Bentham Science Publishers Ltd. ; 2007
    In:  Anti-Cancer Agents in Medicinal Chemistry Vol. 7, No. 2 ( 2007-03-01), p. 223-245
    In: Anti-Cancer Agents in Medicinal Chemistry, Bentham Science Publishers Ltd., Vol. 7, No. 2 ( 2007-03-01), p. 223-245
    Abstract: Angiogenesis, or formation of new blood capillaries from preexisting vessels, plays both beneficial and damaging roles in the organism. It is a result of a complex balance of positive and negative regulators, and vascular endothelial growth factor (VEGF) is one of the most important pro-angiogenic factors involved in tumor angiogenesis. VEGF increases vascular permeability, which might facilitate tumor dissemination via the circulation causing a greater delivery of oxygen and nutrients; it recruits circulating endothelial precursor cells, and acts as a survival factor for immature tumor blood vessels. The endotheliotropic activities of VEGF are mediated through the VEGF-specific tyrosine-kinase receptors: VEGFR-1, VEGFR-2 and VEGFR-3. VEGF and its receptors play a central role in tumor angiogenesis, and therefore the blockade of this pathway is a promising therapeutic strategy for inhibiting angiogenesis and tumor growth. A number of different strategies to inhibit VEGF signal transduction are in development and they include the development of humanized neutralizing anti-VEGF monoclonal antibodies, receptor antagonists, soluble receptors, antagonistic VEGF mutants, and inhibitors of VEGF receptor function. These agents can be divided in two broad classes, namely agents designed to target the VEGF activity and agents designed to target the surface receptor function. The main purpose of this review is to summarize all the available information regarding the importance of the proangiogenic factor VEGF in cancer therapy. After an overview of the VEGF family and their respective receptors, we shall focus our attention on the different VEGF-inhibitors existent nowadays. Agents based upon anti-VEGF therapy have provided solid proofs about their success, and therefore we believe that a critical review is of the utmost importance to help researchers in their future work.
    Type of Medium: Online Resource
    ISSN: 1871-5206
    Language: English
    Publisher: Bentham Science Publishers Ltd.
    Publication Date: 2007
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...